News

Stocktwits on MSN7d

Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...

Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market

Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...
BioPharma Dive7d

Insmed gains US approval of lung disease drug forecast to be blockbuster

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
pharmaphorum7d

Insmed gets first FDA approval for bronchiectasis

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...
Fierce Pharma7d

Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor

With a landmark U.S. approval  Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
TipRanks on MSN10h

Insmed initiated with an Outperform at William Blair

William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with ...
GEN - Genetic Engineering and Biotechnology News2d

StockWatch: After FDA Approval, Analysts Predict Blockbuster Sales for Insmed Drug

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

FDA approves first drug for chronic lung condition bronchiectasis

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...
BioSpace6d

Insmed Wins Approval for First Bronchiectasis Drug and DPP1 Blocker

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

Insmed Gets FDA OK of Brinsupri in Non-Cystic Fibrosis Bronchiectasis

Insmed has won U.S. Food and Drug Administration approval of Brinsupri as the first and only treatment for the chronic lung disease non-cystic fibrosis bronchiectasis. Insmed on Tuesday said the FDA ...
STAT7d

Insmed’s lung disease drug approved in the U.S.

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...
Healio7d

FDA approves brensocatib for non-cystic fibrosis bronchiectasis

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...